The Importance of Biomarker Testing for the Effective Treatment of GIST Patients – LRG Science

This issue of LRG Science presents six case studies as evidence that the practice of biomarker/mutational testing early in a GIST patient's journey is a critical path to the most effective treatment. Each patient was diagnosed with GIST, but did not receive mutational testing early enough to avoid suffering adverse side effects and wasting money on unnecessary, costly drugs.

By |2021-09-27T07:30:29-04:00August 30th, 2021|LRG Science, Mutational Testing, News|

The LRG and NIH Collaborate on Virtual Tumor Boards to Review Challenging Cases

In this issue of LRG Science, we highlight the power of collaboration in medicine with a recap of the Virtual Tumor Board co-hosted with the NIH. Due to the pandemic, The Life Raft Group was asked to organize a Virtual Tumor Board to assure that challenging cases were presented in order to help the patients and their treating physicians develop an effective treatment plan.

By |2020-10-14T16:17:24-04:00October 14th, 2020|LRG Science, News|

The Life Raft Group Announces Collaboration with OHSU on GIST Tissue Bank

In this issue of LRG Science, we release breaking news of our newest collaboration - with OHSU on the GIST Collaborative Tissue Bank. The LRG has a unique patient registry with over 2,000 members and this collaboration is an important example of the vital role patient advocacy groups and academic institutions play in bridging the gap between researchers and motivated patient populations who want to share their clinical histories and tissue to create new treatments and better outcomes. 

By |2020-09-28T15:37:49-04:00September 28th, 2020|LRG Science, News, Tissue Bank|

Survival in Advanced GIST Has Improved Over Time – LRG Science

In this issue of LRG Science, the relationship between overall survival (OS) and access to treatments after imatinib failure is explored. In 2019, the LRG published this research in Clinical Sarcoma Research and this issue includes commentary from experts. LRG Science endeavors to be a respected source of timely, science-based information built on real world data designed for those whose focus is to increase patient survival from GIST and other cancers.

By |2021-08-30T09:41:53-04:00April 1st, 2020|Drug Treatment, LRG Science, News, Research|

First-Line Imatinib More Effective Than Widely Believed – LRG Science

The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.

By |2020-05-01T09:56:32-04:00December 13th, 2019|Drug Treatment, Gleevec, LRG Science, News|

Treatment Responses in SDH-deficient GIST – LRG Science

The latest issue of LRG Science is titled, "Patient-reported Treatment Responses in Known/Likely SDH-deficient GISTS: An Analysis of The Life Raft Group Observational Registry." This study highlights the very unique research role that defines The Life Raft Group. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.

By |2019-12-13T09:39:06-05:00August 13th, 2019|LRG Science, News, SDH-Deficient GIST|

The Life Raft Group Research Model – LRG Science

PDF is available of LRG Science to print here. Real World Evidence in Action Although targeted medicine has brought about immense progress in cancer treatment, there are still enormous challenges [...]

By |2019-05-05T14:20:27-04:00February 21st, 2019|LRG Science, News, Newsletter, Research|
Go to Top